Back to top
more

Pliant Therapeutics (PLRX)

(Real Time Quote from BATS)

$12.15 USD

12.15
39,963

+0.34 (2.88%)

Updated Apr 29, 2024 10:54 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for PLRX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Pliant Therapeutics, Inc. [PLRX]

Reports for Purchase

Showing records 1 - 20 ( 29 total )

Company: Pliant Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

02/28/2024

Company Report

Pages: 8

4Q Recap; Phase 2b BEACON-IPF Trial Continues Enrollment; Week 24 INTEGRIS-PSC Data on Target in Mid-2024; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Pliant Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

02/06/2024

Daily Note

Pages: 5

Bexotegrast Shows Promise in PSC But the Road Ahead Is Far From Clear; Key Value Proposition Remains IPF; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Pliant Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

02/05/2024

Company Report

Pages: 7

320 mg Dose Effect in PSC Remains Positive Across Multiple Endpoints, but ELF Score Is Confounding; Trim PT to $48

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Pliant Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

11/10/2023

Company Report

Pages: 8

3Q Recap; We Look For Late-Breaker at The Liver Meeting 2023 For Additional Data From INTEGRIS-PSC Study; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Pliant Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

11/07/2023

Daily Note

Pages: 5

SITC Presentations Outline Rationale For PLN-101095''s Dual Inhibition of Integrins ávâ8/ávâ1 in Oncology

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Pliant Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

09/27/2023

Company Report

Pages: 9

Interim 12-Week Data From INTEGRIS-PSC Highly Encouraging and Better Than Expected; Raise PT to $52

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Pliant Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

08/29/2023

Daily Note

Pages: 4

Bexotegrast''s Potential in IPF Highlighted in ERS International Congress 2023; P2a INTEGRIS-PSC Data in 3Q; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Pliant Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

08/10/2023

Company Report

Pages: 8

2Q Recap; Phase 2b BEACON-IPF Trial Kicks Off; Phase 2a INTEGRIS-PSC Data This Quarter; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Pliant Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

06/27/2023

Daily Note

Pages: 6

Fibrogen''s Pamrevlumab Exits the IPF Race With Phase 3 Miss; EASL Presentations Highlight Bexotegrast in PSC; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Pliant Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

05/25/2023

Daily Note

Pages: 7

Bexotegrast''s Potential in IPF Highlighted at ATS 2023; Phase 2b BEACON-IPF to Start in Mid-2023 Start; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Pliant Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

05/10/2023

Company Report

Pages: 8

1Q Recap: Phase 2b BEACON-IPF Study to Start Mid-2023; Initial 12-Week Data in PSC in 3Q23; Moderate PT to $50

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Pliant Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

05/02/2023

Daily Note

Pages: 6

Additional Data From Phase 2a INTEGRIS-IPF Study Further Highlights Bexotegrast''s Potential in IPF; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Pliant Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

05/01/2023

Company Report

Pages: 8

Bexotegrast 320 mg Demonstrates Durable Improvements in FVC, QLF and Cough at 24 Weeks; PT Nudged Up to $55

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Pliant Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

03/28/2023

Daily Note

Pages: 4

American Thoracic Society International Conference Presentations Highlight Bexotegrast''s Potential in IPF; Affirm Buy.

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Pliant Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

03/20/2023

Company Report

Pages: 13

Final Bexotegrast 320 mg Data Could Positively Surprise Again; Phase 2b IPF Trial Starts Mid-2023; Affirm Buy, PT to $54

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Pliant Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

11/18/2022

Company Report

Pages: 8

3Q Recap: Data for 320 mg Dose in IPF in Early 1Q23; PSC Data in 3Q23; PLN-101095 to Enter the Clinic; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Pliant Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

09/01/2022

Daily Note

Pages: 3

Latest DSMB Review Confirmed PLN-74809''s Safety At 320 mg Top Dose; Early 2023 Interim Readout on Target; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Pliant Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

08/09/2022

Company Report

Pages: 9

2Q Recap; Positive INTEGRIS-IPF Dataset Provides Strong Rationale to Advance PLN-74809 in IPF; Increasing PT to $53

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Pliant Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

07/11/2022

Daily Note

Pages: 4

Top-line Data From INTEGRIS-IPF Offers Strong Encouragement, But Appears Clouded by Variable Dose Response

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Pliant Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

06/23/2022

Daily Note

Pages: 4

New Data Presentation Highlights Novel Approach For Treatment of Muscular Dystrophies; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party